Abstract:Acetylcholinesterase is involved in the termination of impulse transmission by rapid hydrolysis of the neurotransmitter acetylcholine in numerous cholinergic pathways in the central and peripheral nervous systems. The enzyme inactivation, induced by various inhibitors, leads to acetylcholine accumulation, hyperstimulation of nicotinic and muscarinic receptors, and disrupted neurotransmission. Hence, acetylcholinesterase inhibitors, interacting with the enzyme as their primary target, are applied as relevant drugs and toxins. This review presents an overview of toxicology and pharmacology of reversible and irreversible acetylcholinesterase inactivating compounds. In the case of reversible inhibitors being commonly applied in neurodegenerative disorders treatment, special attention is paid to currently approved drugs (donepezil, rivastigmine and galantamine) in the pharmacotherapy of Alzheimer's disease, and toxic carbamates used as pesticides. Subsequently, mechanism of irreversible acetylcholinesterase inhibition induced by organophosphorus compounds (insecticides and nerve agents), and their specific and nonspecific toxic effects are described, as well as irreversible inhibitors having pharmacological implementation. In addition, the pharmacological treatment of intoxication caused by organophosphates is presented, with emphasis on oxime reactivators of the inhibited enzyme activity administering as causal drugs after the poisoning. Besides, organophosphorus and carbamate insecticides can be detoxified in mammals through enzymatic hydrolysis before they reach targets in the nervous system. Carboxylesterases most effectively decompose carbamates, whereas the most successful route of organophosphates detoxification is their degradation by corresponding phosphotriesterases. 1. CHOLINESTERASES Cholinesterase is a family of enzymes that catalyzes the hydrolysis of the neurotransmitter acetylcholine (ACh) into choline and acetic acid, a reaction necessary to allow a cholinergic neuron to return to its resting state after activation. It involves two types: 1. Acetylcholinesterase (AChE, acetycholine acetylhydrolase, E.C. 3.1.1.7) is found in many types of conducting tissue: nerve and muscle, central and peripheral tissues, motor and sensory fibers, and cholinergic and noncholinergic fibers. The activity of AChE is higher in motor neurons than in sensory neurons [1-3]. AChE is also found in the red blood cell membranes, where it constitutes the Yt blood group antigen. The enzyme exists in multiple molecular forms, which possess similar catalytic properties, but differ in their oligomeric assembly and mode of attachment to the cell surface. In the mammalian brain the majority of AChE occurs as a tetrameric, G4 form (10) with much smaller amounts of a monomeric G1 (4S) form [4]. as plasma cholinesterase, butyrylcholinesterase, or acylcholine acylhydrolase, is found primarily in the liver. Different from AChE, BuChE hydrolyzes butyrylcholine more quickly than ACh [5]. The …

Kinetics of human erythrocyte acetylcholinesterase inhibition by a novel derivative of physostigmine: phenserine.

Kinetics of human acetylcholinesterase inhibition by the novel experimental alzheimer therapeutic agent, tolserine

Species- and concentration-dependent differences of acetyl- and butyrylcholinesterase sensitivity to physostigmine and neostigmine

Optimization and Kinetic Studies of Human Erythrocyte Membrane-Bound Acetylcholinesterase

Human Erythrocyte Acetylcholinesterase Inhibition by Cis-Diamminediaquaplatinum (II): a Novel Kinetic Approach

Kinetic Analysis of the Inhibition of Human Butyrylcholinesterase with Cymserine.

The Preparation and Kinetic Analysis of Multiple Forms of Human Erythrocyte Acetylcholinesterase

Kinetics of Human Erythrocyte Acetylcholinesterase Inhibition by Cis-Diamminediaquaplatinum (Ii)

In vitro kinetic interactions of pyridostigmine, physostigmine and soman with erythrocyte and muscle acetylcholinesterase from different species

Kinetics of Human Serum Butyrylcholinesterase Inhibition by a Novel Experimental Alzheimer Therapeutic, Dihydrobenzodioxepine Cymserine

Characterization of Human Erythrocyte Membrane-Bound Acetylcholinesterase Inhibition by Cisplatin at Reversible Phase.

Biphasic Effect of Eserine and Other Acetylcholinesterase Inhibitors on the Nicotinic Response to Acetylcholine in Cultured Adrenal Chromaffin Cells

Human Platelet Acetylcholinesterase Inhibition by Cyclophosphamide: A Combined Experimental and Computational Approach

Send Orders of Reprints at Reprints@benthamscience.net Acetylcholinesterase Inhibitors: Pharmacology and Toxicology

Current Acetylcholinesterase-Inhibitors: a Neuroinformatics Perspective.

Investigation of the Effect of Lannate on Kinetic Parameters of Acetylcholinesterase: Slightly Concave Mixed-Type of Inhibition System

Design, Synthesis and Pharmacological Evaluation of Chalcone Derivatives As Acetylcholinesterase Inhibitors

Kinetics of the Inhibition of Acetylcholinesterase from Desert Cobra (walterinnesia Aegyptia) Venom by Local Anesthetics: Procaine and Tetracaine

Effect of Malathion on Kinetic Parameters of Acetylcholinesterase (EC 3.1.1.7)in Vitro

Novel chalcone derivatives of ursolic acid as acetylcholinesterase inhibitors: Synthesis, characterization, biological activity, ADME prediction, molecular docking and molecular dynamics studies

Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015)